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Central giant cell granuloma (CGCG), first described by Jaffe in 1953,\[[@ref1]\] is a benign intraosseous lesion consisting of cellular fibrous tissue that contains multiple foci of hemorrhage, aggregations of multinucleated giant cells, and occasionally trabeculae of woven bone that usually involves mandible than maxilla (2:1) before the age of 30 years.\[[@ref2][@ref3]\] Occurrences in other facial bones, such as the sphenoid and temporal, as well as in hand, foot, and humerus, have also been reported.\[[@ref4]--[@ref6]\] A clinically and histologically similar lesion occurs as a result of increased parathyroid hormone (PTH) levels which cause an imbalance between osteoclastic--osteoblastic homeostasis and calcium--phosphate regulation, leading to bone resorption with fibrous replacement of the marrow and thinning of the cortex.\[[@ref7]\] Excessive PTH secretion may be due to problems in the glands themselves, in which case it is referred to as primary hyperparathryroidism and which leads to hypercalcemia. It may also occur in response to low calcium levels, as encountered in various situations such as vitamin D deficiency or chronic kidney disease; this is referred to as secondary hyperparathyroidism. Tertiary hyperparathyroidism has a high PTH and high serum calcium. It is differentiated from primary hyperparathyroidism by a history of chronic kidney failure and secondary hyperparathyroidism, as continuous stimulation of the parathyroids may result in adenoma formation and autonomous PTH secretion.

Often, multiple CGCGs are found to be associated with hyperparathyroidism.\[[@ref8]\] There are no clinical, histological, cytometric, or immunohistochemical differences between the aggressive and nonaggressive CGCGs, and it is found that the giant cell tumors (GCTs) of long bones and the central giant cell tumors (CGCG) of jaws may be just variants of the same disease entity, with age- and site-specific features.\[[@ref9]\]

In all cases, the raised PTH levels are harmful to bone and treatment is often needed. Recent evidence suggests that vitamin D deficiency/insufficiency plays a role in the development of hyperparathyroidism.\[[@ref10]\] Here, we report on a rare case of vitamin D malabsorption and secondary hyperparathyroidism, presenting as an asymptomatic brown tumor of mandible, treated conservatively.
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A 12-year-old female patient reported with the chief complaint of swelling in the right mandibular angle region since 8 months \[[Figure 1](#F1){ref-type="fig"}\]. The swelling was slowly growing, bony hard in consistency, and not associated with any symptoms, non-tender, and not mobile. There were no neurosensory deficits or cervical lymphadenopathy evident. Mouth opening was normal with full complement of teeth present except third molars. Diffuse obliteration of right mandibular buccal vestibule, retromolar trigone, and expansion of lingual cortex distal to mandibular right second molar was evident. None of the mandibular right quadrant teeth were tender or mobile. All mandibular teeth were vital. Radiograph revealed tooth bud of third molar, unilocular radiolucency extending from apical and distal of mandibular right second molar to ramus, with sclerotic border at the body region anteriorly and scalloped at the ramus, expanded, leaving thin cortices toward the lower and posterior border of mandible, the third molar apparently pushed upward when compared with the left mandibular third molar, and no evidence of root resorption \[[Figure 2](#F2){ref-type="fig"}\]. Fine needle aspiration cytology (FNAC) was done with positive aspiration of little frothy appearing blood. Meanwhile, an open curettage biopsy was performed and sent for histopathologic evaluation. The histopathology reported it as CGCG with sections showing fibrocellular connective tissue stroma with numerous plump fibroblasts and multinucleated giant cells, few osteoblasts, and numerous blood vessels \[[Figure 3](#F3){ref-type="fig"}\].

![Preoperative view -- swelling at the right mandibular angle region](IJEM-16-310-g001){#F1}

![Pre op orthopantomogram showing radiolucency at right angle and ramus of mandible with upward displacement of third molar bud](IJEM-16-310-g002){#F2}

![Histopathology showing fibrocellular connective tissue stroma with fibroblasts, giant cells, osteoblasts and blood vessels](IJEM-16-310-g003){#F3}

Considering the histological diagnosis of a giant cell lesion, the patient was subjected for PTH estimation, renal function tests (RFT), and complete blood investigation. The PTH was 635.5 (14.0--72.0) pg/ml, alkaline phosphatase 421 (33--96) U/l, total calcium 7.8 (8.7--10.2) mg/dl and phosphorous was 4.10 (2.5--4.3) mg/dl. Complete skeletal radiographs ruled out the presence of any bony lesions. Serum Vitamin D was not measured due to resource limitations. The patient was treated conservatively with surgical debridement alone using modified Brosch\'s procedure, sacrificing the third molar and preserving the inferior alveolar nerve \[[Figure 4](#F4){ref-type="fig"}\], followed by maxillo-mandibular fixation for 6 weeks. On endocrinologist\'s reference, the patient was diagnosed to be suffering from hypocalcemia/secondary hyperparathyroidism, the cause being nutritional or vitamin D deficiency. She was advised Tab. calcium carbonate, chewable, thrice daily, with cholecalciferol sachet 60 000 U once a week, after a stat dose of Inj. Arachitol 6 lakh unit along with calcium rich diet, and suggestion to increase sunshine exposure through outdoor activities.

![Intra operative view showing post debridement site using Brosch procedure and preserved inferior alveolar nerve](IJEM-16-310-g004){#F4}

The patient was reviewed 6 months postoperatively, and a series of immediate, 2-week, 8-week, and 6-month post-op radiographs \[Figures [5a](#F5){ref-type="fig"}--[c](#F5){ref-type="fig"}\] showed satisfactory evidence of bone formation. A repeat blood examination reported PTH as 27 (14.0--72.0) pg/ml, total calcium as 9.7 mg% (8.7--10.2 mg/dl), phosphorous to be 4.5 mg% (2.5--4.3 mg/dl), and alkaline phosphatase activity as 212 (33--96) U/l, and clinically no neurological deficits were present.

![(a-c) composite picture showing Immediate/8weeks/6months postoperative orthopantomogram](IJEM-16-310-g005){#F5}
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The parathyroid glands, situated behind the thyroid, are not regulated by the pituitary gland, but respond directly to changes in serum ionized calcium concentrations. PTH is a single-chain polypeptide of 84 amino acids, which is synthesized by the chief cells and released in response to a fall in serum ionized calcium concentration. This hormone interacts with vitamin D and its metabolites in regulating calcium absorption and excretion. PTH has direct effects which promote reabsorption of calcium from renal tubules and also has indirect effects, mediated by increased conversion of 25-hydroxycholecalciferol (i.e. vitamin D) to the more potent hormone 1,25-dihydroxycholecalciferol, which results in increased calcium absorption from food and enhanced mobilization of calcium from bone \[[Figure 6](#F6){ref-type="fig"}\].

![Normal functioning of parathyroid glands](IJEM-16-310-g006){#F6}

Vitamin D deficiency can be caused by conditions that result in little exposure to sunlight, such as living in northern latitudes, dark skin, infants or elders having less chance to go outside, and covering one\'s face and body mainly due to religious reasons. Particularly, women may acquire vitamin D deficiency, even though they live in a sunny climate.

PTH plays a central role in regulating calcium homeostasis because vitamin D and dietary calcium are rarely deficient. Moreover, 99% of the total body calcium is in bone, but this pool is in dynamic equilibrium with the extracellular fluid by processes of bone resorption and deposition. The initial effect of PTH on bone is to stimulate osteolysis, returning calcium from bone to extracellular fluid. Prolonged exposure of bone to PTH is associated with increased osteoclastic activity, extensive bone remodeling, and osteoblastic repair. In some species, calcitonin, a hormone secreted from the parafollicular C cells of the thyroid gland, also regulates calcium metabolism. However, although calcitonin is a useful tumor marker in medullary carcinoma of thyroid, it is of no clinical relevance to calcium homeostasis in humans.

It is customary to distinguish three categories of hyperparathyroidism \[[Table 1](#T1){ref-type="table"}\]. In *primary hyperparathyroidism*, there is usually autonomous secretion of PTH by a single parathyroid adenoma varying in size from a few millimeters to several centimeters in diameter, and seen in postmenopausal women. Rare causes include carcinoma of the parathyroids. *Secondary hyperparathyroidism* is present when there is hyperplasia with increased PTH secretion in an attempt to compensate for prolonged hypocalcemia caused by chronic renal failure or prolonged dialysis, or severe malabsorption. In a very small proportion of cases of secondary hyperparathyroidism, continuous stimulation of the parathyroids may result in adenoma formation and autonomous PTH secretion. This is known as *tertiary hyperparathyroidism*.\[[@ref11][@ref12]\]

###### 

Classification of hyperparathyroidism

![](IJEM-16-310-g007)

Primary hyperparathyroidism is the most common of the parathyroid disorders, with a prevalence of about 1 in 800. It is 2--3 times more common in women than men and 90% of the patients are over 50 years of age. It also occurs in all of the familial multiple endocrine neoplasia syndromes. The incidence of primary hyperparathyroidism is 0.2% in patients older than 60 years and the estimated prevalence is over 1%, including undiscovered symptomatic patients.\[[@ref11][@ref13]\] In the present case, primary hyperparathyroidism was ruled out by the absence of adenoma or a glandular hyperplasia.

The various reasons are listed out \[[Table 2](#T2){ref-type="table"}\], which need to be considered as the differential diagnosis in hypocalcemia.\[[@ref12]\] Subtotal thyroidectomy for Graves' disease causes transient hypocalcemia in 10% of patients, 12--36 hours following surgery. Idiopathic hypoparathyroidism may develop at any age, and is sometimes associated with autoimmune disease of the adrenal, thyroid, or ovary, especially in young people. Pseudohypoparathyroidism is usually an autosomal dominant syndrome in which there is tissue resistance to the effects of PTH. The PTH receptor is normal, but there is a defective post-receptor mechanism. In our patient, the lack of dietary calcium and vitamin D deficiency activated the excessive secretion of PTH, which then is known to mobilize calcium from body skeleton, and in the case discussed here, the mandible was involved.

###### 

Differential diagnosis for hypocalcemia
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An increased PTH level in the patient created imbalance in osteoclastic-osteoblastic homeostasis and calcium--phosphorous regulation \[[Figure 7](#F7){ref-type="fig"}\], which presented as CGCG of mandible as a first sign of hyperparathyroidism, which is rare. However, brown tumors in the mandible are diagnosed in 4% of all cases of hyperparathyroidism. The true incidence and prevalence of brown tumor, however, must be higher and the most likely explanation is that in most patients, the jaw lesions are never diagnosed and will spontaneously disappear when the PTH and calcium levels are corrected.\[[@ref7]\]

![Effect of increased parathyroid hormone and homeostasis](IJEM-16-310-g009){#F7}

The recurrence rate of CGCGs after initial conservative surgical therapy (curettage) is reported as 12--37%; repeat curettage usually prevents further recurrence.\[[@ref14]\] But in cases of vitamin D deficiency and secondary hyperparathyroidism, the lesion usually resolves after surgical debridement and replacement therapy.\[[@ref10]\]

Rubio *et al*.\[[@ref15]\] treated two cases with enucleation which included removal of teeth involved in the lesion and the surgical site treated with tricloroacetic acid 50% and cryosurgery, and bone stabilized using reconstruction plate. Bone regeneration has been excellent as the ages of patients were 26 and 9 years, respectively.

Other treatment modalities tried for treating CGCG include intralesional injection of corticosteroids,\[[@ref16]--[@ref19]\] calcitonin,\[[@ref20]--[@ref22]\] cryotherapy,\[[@ref15]\] antiangiogenic therapy with interferons.\[[@ref23][@ref24]\] In a recent review of literature by Lang *et al*.,\[[@ref25]\] they tested the RANK and RANKL (an essential cytokine for osteoclastogenesis, demonstrated in CGCG) inhibitors such as osteoprotegrin (OPG) and monoclonal antibody to RANKL, AMG 162, with promising results when tried with caution. Theoretically, OPG/AMG 162 and calcitonin could be synergistic since OPG/AMG 162 inhibits the formation of osteoclast-like cells, while calcitonin hampers their function. Since RANK and RANKL modulate NF-kappa-B activity, which has a key role in regulation of the immune response, cell growth, differentiation, and apoptosis, the side effects, especially in systemic treatment, warrant careful attention .*Imatinib*, a protein tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors, is found to be an effective anti-osteolytic agent and could therefore be useful in the treatment of skeletal disease involving excessive osteoclast activity, such as CGCG.\[[@ref25]\]

Based on clinical, radiological, and histopathologic findings\[[@ref26][@ref27]\] of our patient, we categorized the condition under nonaggressive type of CGCG and decided for conservative treatment. A modified Brosch\'s procedure\[[@ref28][@ref29]\] was performed with lateral mandibular cortex based on the periosteum and thorough surgical debridement was done. The ramus was stabilized using a 24-G wire and water-tight closure achieved with a tube drain in place. The patient was put on maxilla-- mandibular fixation for 6 weeks and started on medical line of treatment as described above \[[Figure 8](#F8){ref-type="fig"}\]. A 6-month postoperative PTH assay, calcium, phosphorous, and alkaline phosphatase levels showed remarkably reduced values, with homogenous bone opacification at the ramus and body regions.

![Vitamin D synthesis](IJEM-16-310-g010){#F8}
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Vitamin D deficiency, secondary hyperparathyroidism, hypocalcemia, and CGCG as a first presentation in the mandible is relatively a rare combination reported in the literature. There is a possibility of spontaneous regression of lesion once the deficiency is corrected, which could be the reason for less number of reports in the literature. A parathyroid estimation, calcium and phosphorous, alkaline phosphatase levels should be made a mandatory investigation in all cases of CGCG. Though the case treated with conservative surgical debridement and replacement therapy yielded satisfactory results in 6 months, long-term follow-up is necessary to understand the tumor behavior.
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